Relay Therapeutics (RLAY)
(Delayed Data from NSDQ)
$6.48 USD
+0.12 (1.89%)
Updated Jul 8, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RLAY 6.48 +0.12(1.89%)
Will RLAY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RLAY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLAY
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
RLAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
Other News for RLAY
Relay Therapeutics (RLAY) Gets a Buy from Stifel Nicolaus
Relay Therapeutics: A 'Concept' Stock
Largest Clinical-Stage Biotech Drug Stocks Declined 6%
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Relay Therapeutics (RLAY) and BioNTech SE (BNTX)